Acute Lymphoblastic Leukemia in Elderly Patients: A Single Institution’s Experience
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: We investigated the clinical characteristics and prognosis of elderly patients with acute lymphoblastic leukemia (ALL). Methods: We reviewed the clinical data, laboratory findings, bone marrow findings, and cytogenetic analysis of elderly patients (≥ 60 years) with ALL, and data of an additional 101 younger adult patients (< 60 years) with ALL were reviewed for comparison. Results: Twenty-six elderly patients (≥ 60 years) and 101 younger adult patients (< 60 years) with ALL were retrospectively enrolled. The median follow-up duration was 6.0 months (range, 0.4 to 113.2) in the elderly patients and 21.7 months (range, 1.0 to 122.7) in the adult patients. In total, 34.6% (9 patients) of the elderly patients and 24.8% (25 patients) of the adult patients had Philadelphia chromosome positive ALL. The overall complete remission (CR) rate was much higher in the younger than in the elderly patients (94.1% vs. 57.7%, p < 0.001). The median overall survival (OS) of the younger patients (< 60 years) was 26.3 months, whereas that of the elderly patients (≥ 60 years) was 10.3 months (p = 0.003). In the elderly patients with ALL, T cell lineage and the presence of lymphadenopathy were significant prognostic factors for OS in a univariate analysis (p = 0.033 and 0.041, respectively). Conclusions: The outcomes of Korean elderly patients with ALL were poor, and the shorter OS was mainly due to the low CR rate. T-cell lineage and the presence of lymphadenopathy were significant prognostic factors in Korean elderly patients with ALL.
Abstract
Background/Aims: We investigated the clinical characteristics and prognosis of elderly patients with acute lymphoblastic leukemia (ALL). Methods: We reviewed the clinical data, laboratory findings, bone marrow findings, and cytogenetic analysis of elderly patients (≥ 60 years) with ALL, and data of an additional 101 younger adult patients (< 60 years) with ALL were reviewed for comparison. Results: Twenty-six elderly patients (≥ 60 years) and 101 younger adult patients (< 60 years) with ALL were retrospectively enrolled. The median follow-up duration was 6.0 months (range, 0.4 to 113.2) in the elderly patients and 21.7 months (range, 1.0 to 122.7) in the adult patients. In total, 34.6% (9 patients) of the elderly patients and 24.8% (25 patients) of the adult patients had Philadelphia chromosome positive ALL. The overall complete remission (CR) rate was much higher in the younger than in the elderly patients (94.1% vs. 57.7%, p < 0.001). The median overall survival (OS) of the younger patients (< 60 years) was 26.3 months, whereas that of the elderly patients (≥ 60 years) was 10.3 months (p = 0.003). In the elderly patients with ALL, T cell lineage and the presence of lymphadenopathy were significant prognostic factors for OS in a univariate analysis (p = 0.033 and 0.041, respectively). Conclusions: The outcomes of Korean elderly patients with ALL were poor, and the shorter OS was mainly due to the low CR rate. T-cell lineage and the presence of lymphadenopathy were significant prognostic factors in Korean elderly patients with ALL.
참고문헌 (31)
- Baker MA, "The management of leukaemia in the elderly", Baillieres Clin Haematol, 1, pp.427~448 (1987)
- Delannoy A, "Acute lymphoblastic leukemia in the elderly", Eur J Haematol, 45, pp.90~93 (1990)
- Thomas X, "Acute lymphoblastic leukemia in the elderly: The Edouard Herriot Hospital experience", Am J Hematol, 67, pp.73~83 (2001)
- Robak T, "Acute lymphoblastic leukemia in elde rly: the Polish Adult Leukemia Group (PALG) experience", Ann Hematol, 83, pp.225~231 (2004)
- Virgilio JF, "Acute lymphocytic leukemia (ALL) in elderly patients", Hematol Oncol, 11, pp.121~126 (1993)
- Kantarjian HM, "Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen", Br J Haematol, 88, pp.94~100 (1994)
- Spath-Schwalbe E, "Acute lymphoblastic leukemia in patients over 59 years of age: experience in a single center over a 10-year period", Ann Hematol, 69, pp.291~296 (1994)
- Ferrari A, "Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period", Leukemia, 9, pp.1643~1647 (1995)
- Bassan R, "Age-adapted moderatedose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia", Leuk Lymphoma, 22, pp.295~301 (1996)
- Delannoy A, "Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy: a multicentric prospective study in forty patients", Leukemia, 11, pp.1429~1434 (1997), French Group for Treatment of Adult Acute Lymphoblastic Leukemia
- 신현춘, "60세 이상의 급성 골수성 백혈병 115명에 대한 후향적 분석", 대한내과학회지, 70(2), pp.196~206 (2006), 대한내과학회
- Boucheix C, "Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87)", Blood, 84, pp.1603~1612 (1994), French Group on Therapy for Adult Acute Lymphoblastic Leukemia
- Linker CA, "Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report", Blood, 78, pp.2814~2822 (1991)
- Mandelli F, "The GIMEMA ALL 0183 trial: analysis of 10-year follow-up", Br J Haematol, 92, pp.665~672 (1996), GIMEMA Cooperative Group
- Kantarjian HM, "Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia", J Clin Oncol, 18, pp.547~561 (2000)
- Hee Jin Huh, "Prognostic Significance of Multidrug Resistance Gene 1 (MDR1), Multidrug Resistance-related Protein (MRP) and Lung Resistance Protein (LRP) mRNA Expression in Acute Leukemia", Journal of Korean Medical Science, 21(2), pp.253~258 (2006), 대한의학회
- Leith CP, "Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy", Blood, 89, pp.3323~3329 (1997), A Southwest Oncology Group study
- Taylor PR, "Acute lymphoblastic leukaemia in the elderly", Leuk Lymphoma, 13, pp.373~380 (1994)
- Kantarjian H, "Long-term followup results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a doseintensive regimen, in adult acute lymphocytic leukemia", Cancer, 101, pp.2788~2801 (2004)
- Secker-Walker LM, "Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party", Br J Haematol, 96, pp.601~610 (1997)
- Larson RA, "A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111", Blood, 92, pp.1556~1564 (1998)
- Delannoy A, "Treatment of acute lymphoblastic leukemia in the elderly: an evaluation of interferon alpha given as a single agent after complete remission", Leuk Lymphoma, 43, pp.75~81 (2002)
- Bao L, "Adult precursor B lymphoblastic leukemia in Shanghai, China: characterization of phenotype, cytogenetics and outcome for 137 consecutive cases", Int J Hematol, 89, pp.431~437 (2009)
- Westbrook CA, "Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762)", Blood, 80, pp.2983~2990 (1992)
- Thomas X, "Philadelphia chromosome positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome", Hematol Cell Ther, 40, pp.119~128 (1998)
- Gleissner B, "Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis", Blood, 99, pp.1536~1543 (2002)
- "Impact of age on the biology of acute leukemia"[URL]
- Moorman AV, "Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII", Eastern Cooperative Oncology Group (ECOG) 2993 trial, 2007, pp.109, 3189~3197
- Jang SN, "Trends in the Health Status of Older Koreans", JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 58, pp.592~598 (2010), AGS
- Nout RA, "The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer", Breast Cancer Res Treat, 109, pp.567~572 (2008)